Van Lanschot Kempen: strong net profit of €58.3 million
Amsterdam/’s-Hertogenbosch, the Netherlands, 26 August 2021
- Net profitincreased to €58.3million (H1 2020: €9.5million)
- Recordnet AuM inflows at Private Clients of €2.4billion; net outflowsat Wholesale & Institutional Clients of €2.0 billion, due to a fewinstitutional mandates
- Client assets increased to €121.0billionand AuM to €104.2billion
- Strong growth in management fee income
- Strong capital ratio to 21.9% (2020: 24.3%); decrease caused by a more prudent calculation of market risk, among other factors
- Pay out 2019 dividend and remainder 2020 dividend – totalling €1.95 per share in beginning of Q4
Karl Guha, Chairman, said: “It would be fair to say that we have had a good first half of the year. The numbers speak for themselves. The performance was strong across the board. The growth in assets under management in our high yielding Private Clients segment is particularly gratifying – notwithstanding some of the headwinds we have had in our institutional business. We believe that our approach of combining “personal touch”, professional expertise and technology is beginning to bear fruit. There is every reason to believe that we are well positioned for further growth in all our businesses.
“Furthermore, our inorganic growth in assets under management was further strengthened, through our successful acquisitions in the Netherlands and in Belgium. As such, it is an important step towards realising our goal of being the most respected and successful wealth management house in the Benelux.”
Clients assets and assets under management
During the first six months of the year, client assets increased to €121.0 billion (2020: €115.0 billion). Total assets under management (AuM) increased to €104.2 billion (2020: €99.0 billion) on the back of total net inflows of €0.3 billion and market performance of €4.8 billion. We recorded exceptionally high net inflows in AuM at Private Clients to the tune of €2.4 billion and we saw an outflow of a few institutional mandates within Wholesale & Institutional Clients. This has combined with the positive market performance to significantly enhance management fees. Savings and deposits were slightly up at €10.2 billion (2020: €10.1 billion).
Sustainable investing is an important part of our strategy and we have made solid progress in this field; 17% of our own funds are classified as Article 9 (most sustainable), 62% as Article 8 and 21% as Article 6i under the European Sustainable Finance Disclosure Regulation. In addition, AuM that are classified as sustainable within Private Clients rose by 24% to €3.8 billion in the past six months.
Results in the first half of 2021
Net profit increased to €58.3 million in the first six months of 2021 (H1 2020: €9.5 million). Commission income, the very core of our revenues, was up by 18% at €175.7 million (H1 2020: €148.9 million) on the back of higher recurring commissions and solid results at Corporate Finance. The higher AuM base also provides a good starting point for the rest of the year.
Interest income stabilised and amounted to €76.1 million (H1 2020: €77.0 million). During the first half of 2021, we saw this underpinned by some growth in the mortgage loan portfolio and our ability to charge negative interest rates on savings. In order to mitigate this impact for our clients, we introduced the Wealth Management Arrangement, which is meeting a need of our Private Banking clients to retain a proportion of their wealth in savings without paying negative interest.
PERFORMANCE REPORT / PRESENTATION / WEBCAST
For a detailed discussion of Van Lanschot Kempen’s results and balance sheet, please refer to our performance report and presentation on the 2021 half-year results at www.vanlanschotkempen.com/results. In a conference call on 26 August at 9:00 am CET, we will discuss our 2021 half-year results in greater detail. This may be viewed live at www.vanlanschotkempen.com/results and played back at a later date.
For additional information, go to www.vanlanschotkempen.com/financial.
22 September 2021 Extraordinary general meeting
4 October 2021 Ex-dividend date
12 October 2021 2019 dividend and remainder 2020 dividend payment date
29 October 2021 Publication of 2021 third-quarter trading update
24 February 2022 Publication full-year results 2021
Media Relations: +31 20 354 45 85; firstname.lastname@example.org
Investor Relations: +31 20 354 45 90; email@example.com
About Van Lanschot Kempen
Van Lanschot Kempen, a wealth manager operating under the Van Lanschot, Kempen and Evi brand names, is active in Private Banking, Asset Management and Merchant Banking, with the aim of preserving and creating wealth, in a sustainable way, for both its clients and the society of which it is part. Listed at Euronext Amsterdam, Van Lanschot Kempen is the Netherlands’ oldest independent financial services company, with a history dating back to 1737.
For more information, please visit vanlanschotkempen.com
Important legal information and cautionary note on forward-looking statements
This press release may contain forward-looking statements on future events and developments. These forward-looking statements are based on the current insights, information and assumptions of Van Lanschot Kempen’s management about known and unknown risks, developments and uncertainties. Forward-looking statements do not relate strictly to historical or current facts and are subject to such risks, developments and uncertainties which by their very nature fall outside the control of Van Lanschot Kempen and its management.
Actual results, performances and circumstances may differ considerably from these forward-looking statements as a result of risks, developments and uncertainties relating to, but not limited to, (a) estimates of income growth, (b) costs, (c) the macroeconomic and business climate, (d) political and market trends, (e) interest rates and currency exchange rates, (f) behaviour of clients, competitors, investors and counterparties, (g) the implementation of Van Lanschot Kempen’s strategy, (h) actions taken by supervisory and regulatory authorities and private entities, (i) changes in law and taxation, (j) changes in ownership that could affect the future availability of capital, (k) changes in credit ratings and (l) evolution and economic and societal impact of the Covid-19 pandemic.
Van Lanschot Kempen cautions that forward-looking statements in this press release are only valid on the specific dates on which they are expressed, and accepts no responsibility or obligation to revise or update any information, whether as a result of new information or for any other reason.
The figures in this press release have not been audited separately. Small differences are possible in the tables due to rounding. Percentages are calculated based on unrounded figures.
This press release does not constitute an offer or solicitation for the sale, purchase or acquisition in any other way or subscription to any financial instrument and is not a recommendation to perform or refrain from performing any action.
Elements of this press release contain information about Van Lanschot Kempen NV and/or Van Lanschot Kempen Wealth Management NV within the meaning of Article 7(1) to (4) of EU Regulation No. 596/2014.
This press release is a translation of the Dutch language original and is provided as a courtesy only. In the event of any disparities, the Dutch language version will prevail. No rights can be derived from any translation thereof.
i From the end of 2022, the funds will apply Article 7 prescribing transparency on negative sustainability effects.
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Nordic American Tankers Ltd (NYSE: NAT) – Purchase of NAT shares by Herbjorn Hansson, Founder, Chairman & CEO of NAT17.9.2021 15:41:35 CEST | Press release
Friday, September 17 , 2021 Dear Shareholders and Investors, Herbjorn Hansson has today bought 75,000 shares in NAT at USD 2.3273 per share. As in the past, the Hansson family is one of the largest shareholders in NAT. Sincerely, Herbjorn Hansson Founder, Chairman & CEO Nordic American Tankers Ltd. www.nat.bm CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS Matters discussed in this press release may constitute forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides safe harbor protections for forward-looking statements in order to encourage companies to provide prospective information about their business. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements, which are other than statements of historical facts. The Company desires to take advantage of the safe harbor provisions of the Private Securities Litigation Reform Act
Novartis announces findings from a real-world study of alpelisib demonstrating clinical benefit in people with PIK3CA-Related Overgrowth Spectrum (PROS)17.9.2021 13:30:00 CEST | Press release
PROS is a spectrum of rare disorders caused by PIK3CA mutations and is characterized by atypical, visible overgrowths and anomalies in blood vessels, the lymphatic system and other tissues At 24 weeks, 38% of patients achieved ≥20% reduction in the volume of the PROS lesions assessed in the primary endpoint analysis; no patients experienced disease progression or death Alpelisib is the first potential treatment to specifically address the root cause of PROS conditions EPIK-P1 study findings presented at ESMO Virtual Congress 2021 support FDA submission Basel, September 17, 2021— Novartis today announced important findings from a real-world study evaluating the safety and efficacy of alpelisib for people living with PIK3CA-Related Overgrowth Spectrum (PROS) who received treatment daily for at least 24 weeks. Results from EPIK-P1 showed alpelisib effectively reduced volume of clinically significant PROS-related lesions and improved signs and symptoms in pediatric and adult patients. Resu
GALAPAGOS ANNOUNCES POSITIVE CHMP OPINION FOR JYSELECA® (FILGOTINIB) FOR THE TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS17.9.2021 13:15:00 CEST | Press release
Mechelen, Belgium;17September 2021;13.15 CET; Galapagos NV (Euronext & Nasdaq: GLPG) announced todaythatthe European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issueda positive opinion for Jyseleca® (filgotinib), a once-daily, oral, JAK1preferential inhibitor for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent. Following this positive opinion, a final decision from the European Commission is expected later this year. The CHMP positive opinion is based on data from the pivotal Phase 2b/3 SELECTION program, which evaluated filgotinib as an induction and maintenance therapy in adult patients with moderately to severely active UC who have failed conventional therapy or biologics. SELECTION comprised two placebo-controlled induction studies, one in biologic-naive patients and the o
Roche receives positive CHMP opinion for Gavreto® (pralsetinib) for the treatment of adults with RET fusion-positive advanced non-small cell lung cancer17.9.2021 13:10:00 CEST | Press release
Gavreto showed robust and durable clinical responses in people with NSCLC with RET fusionsIf approved, Gavreto will be the first and only targeted treatment approved by the EMA that includes first-line treatment of people with RET fusion-positive advanced NSCLC Basel, 17 September 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Gavreto® (pralsetinib) as a monotherapy for the treatment of adult patients with rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor. “This positive CHMP opinion for Gavreto represents another important step towards our goal of providing effective therapeutics that target genomic drivers of disease for as many cancer patients as possible," said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Developmen
Elina Stråhlman appointed as Enento Group’s acting CEO17.9.2021 13:00:00 CEST | Press release
ENENTO GROUP PLC, STOCK EXCHANGE RELEASE ON 17 SEPTEMBER 2021 AT 2.00 P.M. EEST Elina Stråhlman appointedas Enento Group’s acting CEO As communicated with a stock exchange release on 21 April 2021, Enento Group Plc’s current CEO Jukka Ruuska has given notice of his resignation from the company no later than 31 October 2021. As announced in July, Jeanette Jäger will start as the new CEO and member of the Executive Management Team on 1 January 2022. Since 2016 she has worked in the Swedish company Bankgirot, first as VP Digital Services and from 2017 as CEO of Bankgirot. Enento Group's Board of Directors has today appointed Elina Stråhlman, the Group’s CFO, as an acting CEO for the interim period from 1 November 2021 to 31 December 2021. ENENTO GROUP PLC For further information: Jukka Ruuska CEO Tel. +358 10 270 7111 Distribution: Nasdaq Helsinki Major media enento.com/investors Enento Group is a Nordic knowledge company powering society with intelligence since 1905. We collect and trans
Fobi Launches Connected Retail Commerce Solution At Industry’s Premier Event For Convenience, Grocers and CPG Brands17.9.2021 12:00:00 CEST | Press release
Fobi CEO Rob Anson and Senior Vice President of Business Development Mike Canevaro to launch new Personalized Digital Receipt Marketing Solution at GroceryShop to be held September 19-22 in Las Vegas, Nevada VANCOUVER, British Columbia, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Fobi AI Inc. (TSX.V: FOBI) (OTCQB: FOBIF) (the "Company" or "Fobi"), a global leader in providing real-time data analytics through artificial intelligence to drive customer activation and engagement, is excited to announce the launch of its latest solution. The Fobi connected retail commerce solution will support real-time POS data connectivity across all banners and channels, in-store, online and mobile to provide retailers and CPG manufacturers with the ability to deliver automated and personalized marketing at scale. PERSONALIZED MARKETING TO EMPOWER CPG BRANDS BY PROVIDING THEM WITH DIRECT ACCESS TO ENGAGE CONSUMERS WITH PROMOTIONS AND CAMPAIGN ACTIVATION MEASUREMENT Fobi will now enable manufacturer brands to gain
RESULT OF RIKSBANK REVERSED AUCTIONS SEK GOVERNMENT BONDS17.9.2021 10:07:00 CEST | Press release
Auction date2021-09-17Loan1059Coupon1.00 %ISIN-codeSE0007125927Maturity2026-11-12Tendered volume, SEK mln500 +/- 250Volume offered, SEK mln1,000Volume bought, SEK mln500Number of bids2Number of accepted bids1Average yield-0.028Lowest accepted yield-0.028Highest yield-0.028% accepted at lowest yield 100.00 Auction date2021-09-17Loan1062Coupon0.125 %ISIN-codeSE0013935319Maturity2031-05-12Tendered volume, SEK mln750 +/- 350Volume offered, SEK mln1,750Volume bought, SEK mln750Number of bids5Number of accepted bids1Average yield0.277Lowest accepted yield0.277Highest yield0.277% accepted at lowest yield 100.00